{
  "_metadata": {
    "version": "2.0",
    "ticker": "NUVL",
    "asset_id": "neladalkib",
    "internal_id": "NVL-655",
    "data_source": "Nuvalent Overview January 12, 2026; Drilon et al ESMO 2024",
    "extraction_date": "2026-02-04",
    "last_updated": "2026-02-04"
  },
  "asset": {
    "name": "neladalkib",
    "internal_id": "NVL-655",
    "modality": "Small molecule tyrosine kinase inhibitor",
    "route": "Oral, once daily",
    "dose": "150 mg QD (RP2D)",
    "formulation": "Oral pill"
  },
  "target": {
    "primary_target": "ALK",
    "target_class": "Receptor tyrosine kinase",
    "biology": {
      "function": "ALK (anaplastic lymphoma kinase) is a receptor tyrosine kinase that when fused to various partner genes (e.g., EML4-ALK) creates oncogenic fusion proteins driving tumor growth through constitutive kinase activation",
      "prevalence": "~3-5% of NSCLC; majority diagnosed at advanced/metastatic stage",
      "patient_demographics": "Often younger patients; significant impact on quality of life",
      "cns_involvement": {
        "at_diagnosis": "30-40% present with brain metastases",
        "overall": "~50% develop brain metastases over disease course"
      },
      "resistance_mechanisms": {
        "single_mutations": {
          "after_2g_tki": "~50% single resistance mutations (alectinib, brigatinib, ceritinib)",
          "after_sequential_2g_3g": "~75% single resistance mutations",
          "common_mutations": ["G1202R", "I1171N", "F1174L", "V1180L", "L1196M", "L1198F"]
        },
        "compound_mutations": {
          "after_sequential_2g_3g": "~25-50% compound mutations",
          "examples": ["G1202R/T1151M", "G1202R/F1174L", "G1202R/L1196M", "G1202R/L1198F", "G1202R/G1269A", "I1171N/L1198F"]
        }
      }
    },
    "genetic_validation": {
      "oncogenic_driver": "Yes - ALK fusions are validated oncogenic drivers in NSCLC, ALCL, and IMT",
      "predictive_biomarker": "ALK fusion status by FISH, IHC, or NGS",
      "therapeutic_precedent": "Multiple approved ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib)"
    },
    "why_good_target": {
      "rationale": [
        "Validated oncogenic driver with proven therapeutic tractability",
        "Next-gen TKIs transforming durability expectations (lorlatinib 1L mPFS not reached at 60 months)",
        "Younger patient population with potential for chronic disease management",
        "Current best therapies (lorlatinib) have TRK-related CNS toxicities limiting tolerability"
      ],
      "unmet_need": [
        "No approved therapy active after sequential 2G→3G TKIs",
        "TRK-related CNS adverse events in >50% of lorlatinib patients",
        "38% of lorlatinib patients no longer on therapy by 24 months in 1L",
        "Compound mutations present therapeutic challenge"
      ]
    }
  },
  "mechanism": {
    "mechanism_of_action": "ALK-selective, TRK-sparing tyrosine kinase inhibitor",
    "binding_mode": "ATP-competitive kinase inhibitor designed to fit the ALK kinase domain including mutant forms while avoiding TRK binding",
    "selectivity_profile": {
      "alk_vs_trkb": ">20x selectivity for ALK over TRKB across single and compound mutants",
      "comparison_to_lorlatinib": "Lorlatinib is a dual TRK/ALK inhibitor with minimal selectivity"
    },
    "in_vitro_activity": {
      "range": "IC50 = 0.1-30 nM against ALK-driven cell lines",
      "coverage": "Potent activity against single and compound ALK mutants including G1202R combinations"
    },
    "in_vivo_activity": {
      "description": "Tumor regression at well-tolerated doses in ALK models including single and compound mutants",
      "models": ["No resistance mutations", "G1202R/L1196M", "I1171N", "G1202R/T1151M", "G1202R/G1269A"]
    },
    "brain_penetration": {
      "kp_uu": "~0.4 (unbound brain:plasma ratio)",
      "comparison": "Similar to preclinical observations for lorlatinib"
    }
  },
  "clinical_data": {
    "trials": {
      "alkove_1": {
        "trial_name": "ALKOVE-1",
        "clinicaltrials_gov": "NCT05384626",
        "design": "Global first-in-human Phase 1/2, open-label, multi-cohort",
        "phase_1_initiation": "June 2022",
        "phase_2_initiation": "February 2024 (RP2D: 150 mg QD)",
        "registration_intent": "Yes, for TKI pre-treated ALK+ NSCLC"
      },
      "alkazar": {
        "trial_name": "ALKAZAR",
        "design": "Phase 3 randomized controlled trial vs alectinib",
        "population": "TKI-naïve ALK+ NSCLC",
        "target_enrollment": "~450 patients",
        "randomization": "1:1 neladalkib vs alectinib",
        "sites": "~160 sites across North America, Europe, Asia, Latin America",
        "status": "Enrollment ongoing"
      }
    },
    "enrollment_alkove_1": {
      "as_of_august_29_2025": 781,
      "phase_1": 133,
      "phase_2": 648,
      "enrollment_trajectory": [
        {"date": "June 2022", "n": 0, "milestone": "Phase 1 initiation"},
        {"date": "August 2023", "n": 93, "milestone": "Phase 1"},
        {"date": "February 2024", "n": 133, "milestone": "Transition to Phase 2"},
        {"date": "September 2024", "n": 362, "milestone": "Phase 1+2"},
        {"date": "December 2024", "n": 596, "milestone": "Phase 1+2"},
        {"date": "March 2025", "n": 762, "milestone": "Phase 1+2 (transitioned to EAP for adult TKI pre-treated)"},
        {"date": "August 29 2025", "n": 781, "milestone": "Phase 1+2"}
      ]
    },
    "data_cutoff": "August 29, 2025",
    "populations": {
      "pivotal_safety": {
        "n": 656,
        "description": "ALK+ NSCLC treated at RP2D as of August 29, 2025",
        "median_duration_exposure": "6.0 months (range 0.1-28.4)"
      },
      "tki_pretreated_efficacy": {
        "n": 253,
        "description": "Treated at RP2D by September 30, 2024 to allow ≥6 months DOR follow-up",
        "note": "Includes 25 patients with other oncogenic drivers in addition to ALK"
      },
      "tki_naive_preliminary": {
        "n": 44,
        "description": "Exploratory cohort in ALKOVE-1",
        "note": "No patients with other oncogenic drivers in addition to ALK"
      }
    },
    "tki_pretreated_results": {
      "population_characteristics": {
        "overall": {
          "n": 253,
          "median_prior_lines": "3 (range 1-11)",
          "prior_chemotherapy": "51%",
          "2_or_more_prior_alk_tkis": "78% (of whom 91% received prior lorlatinib)",
          "secondary_alk_g1202r": "19%",
          "any_alk_mutation": "36% (91/253)",
          "compound_mutations": "17% (43/253)",
          "active_cns_disease": "40%"
        },
        "lorlatinib_naive_subgroup": {
          "n": 63,
          "percent_of_overall": "25%",
          "prior_chemotherapy": "25%",
          "1_or_more_prior_2g_tki": "100%",
          "prior_alectinib_only": "70% (44/63)",
          "secondary_alk_g1202r": "19%",
          "active_cns_disease": "35%"
        }
      },
      "efficacy_overall": {
        "n": 253,
        "orr": "31% (79/253, includes 2 unconfirmed PR) [95% CI: 26, 37]",
        "dor_6_months": "76% [95% CI: 64, 84]",
        "dor_12_months": "64% [95% CI: 51, 75]",
        "dor_18_months": "53% [95% CI: 34, 68]",
        "median_dor": "Not evaluable",
        "median_followup": "11.3 months"
      },
      "efficacy_g1202r_mutation": {
        "n": 47,
        "orr": "68% (32/47, includes 1 unconfirmed PR) [95% CI: 53, 81]",
        "dor_6_months": "84% [95% CI: 65, 93]",
        "dor_12_months": "80% [95% CI: 61, 91]",
        "dor_18_months": "70% [95% CI: 42, 86]"
      },
      "efficacy_lorlatinib_naive": {
        "n": 63,
        "orr": "46% (29/63) [95% CI: 33, 59]",
        "dor_6_months": "89% [95% CI: 69, 96]",
        "dor_12_months": "80% [95% CI: 58, 91]",
        "dor_18_months": "60% [95% CI: 19, 85]",
        "median_dor": "Not evaluable"
      },
      "efficacy_lorlatinib_naive_g1202r": {
        "n": 12,
        "orr": "83% (10/12) [95% CI: 52, 98]",
        "dor_6_months": "90% [95% CI: 47, 99]",
        "dor_12_months": "77% [95% CI: 34, 94]",
        "dor_18_months": "77% [95% CI: 34, 94]"
      },
      "efficacy_1_prior_2g_only": {
        "n": 46,
        "description": "1 prior 2G ALK TKI (alectinib n=44 or brigatinib n=2) ± chemo",
        "orr": "48% (22/46)",
        "dor_12_and_18_months": "74% [95% CI: 48, 88]",
        "median_dor": "Not evaluable"
      },
      "efficacy_lorlatinib_experienced": {
        "n": 190,
        "orr": "26% (50/190, includes 2 unconfirmed PR)",
        "median_dor": "17.6 months [95% CI: 6.9, NE]"
      },
      "efficacy_compound_mutations": {
        "n": 43,
        "description": "≥2 prior ALK TKIs with compound mutations",
        "orr": "58% (25/43, includes 1 unconfirmed PR)",
        "dor_12_months": "69% [95% CI: 45, 84]",
        "median_dor": "Not evaluable"
      },
      "intracranial_activity": {
        "measurable_cns_lesions_any_prior_tki": {
          "n": 92,
          "ic_orr": "32% (29/92, includes 2 unconfirmed PR) [95% CI: 22, 42]",
          "ic_cr": "13% (12/92, includes 1 unconfirmed CR with prior confirmed PR)",
          "ic_dor_6_months": "81% [95% CI: 59, 91]",
          "ic_dor_12_months": "71% [95% CI: 48, 85]",
          "ic_dor_18_months": "71% [95% CI: 48, 85]",
          "median_ic_dor": "21.6 months - emerging, continues to mature"
        },
        "measurable_cns_lesions_lorlatinib_naive": {
          "n": 24,
          "ic_orr": "63% (15/24, includes 2 unconfirmed PR) [95% CI: 41, 81]",
          "ic_cr": "21% (5/24, includes 1 unconfirmed CR with prior confirmed PR)",
          "ic_dor_6_months": "92% [95% CI: 57, 99]",
          "ic_dor_12_months": "92% [95% CI: 57, 99]",
          "ic_dor_18_months": "92% [95% CI: 57, 99]"
        },
        "lorlatinib_experienced_measurable_cns": {
          "n": 68,
          "ic_orr": "21% (14/68)",
          "ic_dor_6_months": "71% [95% CI: 41, 88]",
          "ic_dor_12_and_18_months": "55% [95% CI: 26, 77]",
          "median_ic_dor": "Not evaluable"
        }
      }
    },
    "tki_naive_results_alkove1_exploratory": {
      "population": {
        "n": 44,
        "description": "Exploratory TKI-naïve cohort in ALKOVE-1"
      },
      "efficacy": {
        "orr": "86% (38/44, 4 CRs, includes 2 unconfirmed PR and 1 unconfirmed CR with prior confirmed PR)",
        "dor_6_and_12_months": "91% [95% CI: 70, 98]",
        "dor_range": "1.7+ to 14.8+ months",
        "progression_events_among_responders": 2
      },
      "intracranial_activity": {
        "n": 9,
        "ic_orr": "78% (7/9, 4 IC-CRs, includes 1 unconfirmed CR with prior confirmed PR)",
        "cns_progression_events": 0,
        "ic_dor_range": "3.1+ to 7.0+ months"
      },
      "note": "Global enrollment of TKI-naïve patients ongoing in ALKAZAR Phase 3"
    },
    "safety": {
      "population": 656,
      "dose_reduction_due_to_teae": "17%",
      "dose_reduction_reasons_1_percent_or_more": ["ALT increased (10%)", "AST increased (8%, not mutually exclusive - 11% for any transaminase)"],
      "discontinuation_due_to_teae": "5%",
      "discontinuation_reasons_1_percent_or_more": ["ALT increased (1.8%)", "AST increased (1.2%)"],
      "teaes_15_percent_or_more": [
        {"term": "ALT increased", "any_grade": "47%", "grade_3_plus": "20%"},
        {"term": "AST increased", "any_grade": "44%", "grade_3_plus": "16%"},
        {"term": "Constipation", "any_grade": "28%", "grade_3_plus": "0.2%"},
        {"term": "Dysgeusia", "any_grade": "23%", "grade_3_plus": "0%"},
        {"term": "Peripheral edema", "any_grade": "18%", "grade_3_plus": "0.3%"},
        {"term": "Cough", "any_grade": "16%", "grade_3_plus": "0.5%"},
        {"term": "Nausea", "any_grade": "16%", "grade_3_plus": "0.8%"}
      ],
      "transaminase_management": {
        "observation": "Most were asymptomatic lab abnormalities, low-grade, transient, and reversible with dose interruptions or reductions",
        "preliminary_trend": "Increased incidence in less heavily pre-treated patients",
        "mitigation": "Enhanced monitoring and prompt dose interventions implemented in ALKAZAR Phase 3 protocol"
      },
      "key_safety_message": "Generally well-tolerated, consistent with ALK-selective, TRK-sparing design; no TRK-related neurotoxicities observed"
    }
  },
  "alk_solid_tumors_beyond_nsclc": {
    "enrollment": "Ongoing in Phase 2 portion of ALKOVE-1",
    "tumor_types_observed": [
      "Inflammatory myofibroblastic tumor (IMT) - ~50% ALK+",
      "Neuroblastoma - ~6-16% ALK altered",
      "Sarcomas - ~1-2.4% ALK+",
      "Peritoneal mesothelioma - ~3-13% ALK+",
      "Renal cell carcinoma",
      "Colorectal cancer",
      "Pancreatic adenocarcinoma",
      "Salivary duct carcinoma",
      "Others"
    ],
    "preliminary_data": {
      "n": 34,
      "overall_orr": "44% (15/34) by investigator assessment",
      "alk_tki_naive": "9/13 responded",
      "alk_tki_pretreated": "6/21 responded",
      "note": "Durable responses observed including intracranial CR in patient who received prior alectinib"
    }
  },
  "investment_analysis": {
    "stage_value": "Late-stage Phase 2 (pivotal data); Phase 3 ongoing vs alectinib",
    "differentiation_strength": "Strong - only ALK-selective, TRK-sparing inhibitor",
    "competitive_position": "Potentially best-in-class for tolerability; durable activity in lorlatinib-experienced patients",
    "data_quality": "High - pivotal data from global Phase 1/2 with BICR",
    "regulatory_pathway": "NDA submission planned 1H 2026 for TKI pre-treated",
    "commercial_potential": {
      "addressable_market": "~3-5% of NSCLC; US peak sales opportunity $1.35B-2.0B",
      "pricing_assumptions": "~$22,500/month (lorlatinib 2026 pricing)",
      "key_commercial_factors": [
        "Only option active after sequential 2G→3G TKIs",
        "TRK-sparing design addresses major lorlatinib limitation",
        "ALKAZAR superiority vs alectinib would transform 1L landscape"
      ]
    },
    "key_data_to_watch": [
      "NDA submission timing (1H 2026)",
      "ALKAZAR Phase 3 enrollment and data readout",
      "Long-term durability follow-up in lorlatinib-experienced",
      "ALK+ solid tumors beyond NSCLC development"
    ]
  },
  "catalysts": [
    {
      "event": "NDA submission for TKI pre-treated ALK+ NSCLC",
      "timing": "1H 2026",
      "significance": "Regulatory filing for second approval pathway"
    },
    {
      "event": "Pre-NDA meeting with FDA",
      "timing": "2026",
      "significance": "Alignment on regulatory path"
    },
    {
      "event": "ALKAZAR Phase 3 enrollment milestones",
      "timing": "Throughout 2026",
      "significance": "Progress toward 1L head-to-head vs alectinib readout"
    },
    {
      "event": "Continued enrollment for ALK+ solid tumors and adolescent ALK+ NSCLC",
      "timing": "Ongoing",
      "significance": "Potential for broader label"
    }
  ]
}
